Literature DB >> 16545378

The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves.

Stefan Mahrhold1, Andreas Rummel, Hans Bigalke, Bazbek Davletov, Thomas Binz.   

Abstract

Botulinum neurotoxins (BoNTs) inhibit neurotransmitter release by selectively cleaving core components of the vesicular fusion machinery. The synaptic vesicle proteins Synaptotagmin-I and -II act as receptors for BoNT/B and BoNT/G. Here we show that BoNT/A also interacts with a synaptic vesicle protein, the synaptic vesicle glycoprotein 2C (SV2C), but not with the homologous proteins SV2A and SV2B. Binding of BoNT/A occurs at the membrane juxtaposed region preceding transmembrane domain 8. A peptide comprising the intravesicular domain between transmembrane domains 7 and 8 specifically reduces the neurotoxicity of BoNT/A at phrenic nerve preparations demonstrating the physiological relevance of this interaction.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16545378     DOI: 10.1016/j.febslet.2006.02.074

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  110 in total

1.  Comparison of analgesic effects of single versus repeated injection of botulinum toxin in orofacial formalin test in rats.

Authors:  Ivica Matak; Ivana Stracenski; Zdravko Lacković
Journal:  J Neural Transm (Vienna)       Date:  2012-06-17       Impact factor: 3.575

2.  SNARE tagging allows stepwise assembly of a multimodular medicinal toxin.

Authors:  Frédéric Darios; Dhevahi Niranjan; Enrico Ferrari; Fan Zhang; Mikhail Soloviev; Andreas Rummel; Hans Bigalke; Jason Suckling; Yuri Ushkaryov; Nikolay Naumenko; Anastasia Shakirzyanova; Rashid Giniatullin; Elizabeth Maywood; Michael Hastings; Thomas Binz; Bazbek Davletov
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-04       Impact factor: 11.205

3.  [Botulinum toxin in the treatment of adult spasticity. An interdisciplinary German 10-point consensus 2010].

Authors:  J Wissel; M auf dem Brinke; M Hecht; C Herrmann; M Huber; S Mehnert; I Reuter; A Schramm; A Stenner; C van der Ven; M Winterholler; A Kupsch
Journal:  Nervenarzt       Date:  2011-04       Impact factor: 1.214

Review 4.  From poison to remedy: the chequered history of botulinum toxin.

Authors:  F J Erbguth
Journal:  J Neural Transm (Vienna)       Date:  2007-04-26       Impact factor: 3.575

5.  Generation of high-titer neutralizing antibodies against botulinum toxins A, B, and E by DNA electrotransfer.

Authors:  C Trollet; Y Pereira; A Burgain; E Litzler; M Mezrahi; J Seguin; M Manich; M R Popoff; D Scherman; P Bigey
Journal:  Infect Immun       Date:  2009-02-23       Impact factor: 3.441

6.  Bimodal modulation of the botulinum neurotoxin protein-conducting channel.

Authors:  Audrey Fischer; Yuya Nakai; Lisa M Eubanks; Colin M Clancy; William H Tepp; Sabine Pellett; Tobin J Dickerson; Eric A Johnson; Kim D Janda; Mauricio Montal
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-21       Impact factor: 11.205

7.  Single molecule detection of intermediates during botulinum neurotoxin translocation across membranes.

Authors:  Audrey Fischer; Mauricio Montal
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-11       Impact factor: 11.205

8.  Identification of the synaptic vesicle glycoprotein 2 receptor binding site in botulinum neurotoxin A.

Authors:  Jasmin Strotmeier; Stefan Mahrhold; Nadja Krez; Constantin Janzen; Jianlong Lou; James D Marks; Thomas Binz; Andreas Rummel
Journal:  FEBS Lett       Date:  2014-02-25       Impact factor: 4.124

Review 9.  Evidence based medicine on the use of botulinum toxin for headache disorders.

Authors:  W J Schulte-Mattler; E Leinisch
Journal:  J Neural Transm (Vienna)       Date:  2007-11-12       Impact factor: 3.575

10.  Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons.

Authors:  Min Dong; Huisheng Liu; William H Tepp; Eric A Johnson; Roger Janz; Edwin R Chapman
Journal:  Mol Biol Cell       Date:  2008-09-24       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.